
## ALKEM Daily Closing One Year Price Chart



Name	Mar Cap (Rs. Cr.)	P/E	ROE	Sales(G) QoQ	Sales(G) QYoY	PAT(G) QoQ	PAT(G) QYoY
Dr Reddy's Labs	98240.34	18.32	21.39%	4.27%	15.81%	11.83%	1.69%
Lupin	91754.36	31.99	14.14%	1.67%	10.97%	0.30%	39.48%
Zydus Lifesci.	85077.34	18.76	20.67%	0.61%	16.96%	12.39%	33.34%
Aurobindo Pharma	70361.93	19.80	11.53%	2.34%	8.53%	3.50%	-9.69%
Alkem Lab	59817.47	26.75	18.11%	-2.88%	13.84%	5.36%	35.39%

Aspect	Commentary		
Revenue	Revenue grew 4.08% YoY to Rs.9507 Cr, driven by domestic formulations contributing 70% and international markets 30%. Quarterly revenue declined 2.89% QoQ, reflecting temporary challenges. Strong domestic performance and expanding global presence support sustainable growth.		
Profit & Loss	Operating profit reached Rs.2326 Cr, with a margin of 24.5%. PAT grew 57.38% YoY to Rs.1802 Cr, showcasing operational efficiency. Quarterly PAT growth of 5.3% reflects resilience despite revenue decline. EPS growth of 33.56% highlights shareholder value creation.		
Profitability Matrix	Operating profit margin of 24.5% and EBITDA margin of 23.92% indicate robust profitability. Net profit margin of 18.5% underscores efficient cost management. High RoIC of 25% reflects strong returns on invested capital, supporting long-term growth.		
Valuation Matrix	Trailing P/E of 26.8 and PEG ratio of 1.52 suggest reasonable valuation given growth prospects. EV/EBITDA of 21.1 reflects premium valuation due to strong fundamentals. Dividend yield of 0.80% offers moderate income potential for investors.		
Growth (YoY)	Sales grew 4.08% YoY, driven by domestic formulations and international expansion. PAT growth of 57.38% reflects operational efficiency and cost optimization. EPS growth of 33.56% highlights profitability improvement and shareholder value creation.		
Growth (QoQ)	Sales declined 2.89% QoQ, reflecting temporary challenges. PAT grew 5.3% QoQ, showcasing resilience despite revenue decline. Strong PAT growth QYoQ of 35.47% highlights operation efficiency and ability to navigate short-term headwinds effectively.		
Capital Allocation	RoE of 18.1% and RoCE of 18.4% indicate efficient capital utilization. RoIC of 25% reflects strong returns on invested capital. Cash equivalents of Rs.1284 Cr and low debt/equity ratio of 0.05 highlight a healthy balance sheet and financial stability.		
Holdings	Promoter holding of 55.7% reflects strong ownership confidence. FII and DII holdings of 9.4% an 19.4% indicate institutional interest. Public holding of 16% ensures liquidity. Market cap of Rs.5981 Cr underscores the company's significant market presence.		
Leverage	Debt/equity ratio of 0.05 and total debt of Rs.619 Cr highlight minimal leverage, ensuring financial stability. Enterprise value of Rs.59152 Cr reflects strong market positioning. Healthy balance sheet supports growth initiatives and mitigates financial risks.		